Does Security Health Plan Cover Adderall?

What Is Adderall and Why Does Coverage Get Complicated?

Adderall is a Schedule II controlled substance combining four amphetamine salts. The FDA first approved the immediate-release (IR) formulation in 1996 and the extended-release capsule (Adderall XR) in 2001 for attention-deficit/hyperactivity disorder. [1] Because it carries abuse potential, every insurer, including Security Health Plan, applies additional administrative layers that do not apply to most non-controlled medications.

The Controlled-Substance Layer

The DEA's Schedule II classification means pharmacies cannot dispense Adderall on a refill. Each fill requires a new prescription. [2] Insurers mirror this regulatory caution with prior authorization and quantity limits. Security Health Plan's utilization management criteria for stimulants align with this regulatory framework.

Generic vs. Brand Price Differences

Generic mixed amphetamine salts (MAS IR, MAS XR) entered the market in 2002 for IR and 2009 for XR. [3] Brand-name Adderall XR carries a list price exceeding $300 per month at many Wisconsin pharmacies. The generic equivalent costs $30 to $80 per month without insurance, and significantly less with formulary coverage. That cost gap is exactly why insurers build step-therapy requirements into stimulant coverage: they want members to try the generic before the plan pays for brand.

How ADHD Prevalence Drives Formulary Decisions

ADHD affects an estimated 9.4% of U.S. Children aged 2 to 17 and roughly 4.4% of adults, according to 2023 CDC data. [4] With millions of prescriptions written annually, stimulant coverage policies carry substantial actuarial weight. Security Health Plan serves primarily Wisconsin members, where ADHD diagnosis and treatment rates track closely with national averages. High claim volume pushes formulary managers to apply strict tier placement and PA rules.

Does Security Health Plan's Formulary Include Adderall?

Generic amphetamine/dextroamphetamine is listed on the Security Health Plan formulary for most commercial and Medicare Advantage plans, though tier placement changes each plan year. Brand-name Adderall XR may appear on the formulary at a higher tier or require non-formulary exception depending on the benefit year you are in. Always verify your specific plan's current formulary at the Security Health Plan member portal or call the pharmacy benefit number on your insurance card.

Tier Placement and Cost Sharing

Most Security Health Plan commercial plans use a four- or five-tier formulary structure:

• Tier 1: Preferred generics (low copay, $0, $15)
• Tier 2: Non-preferred generics or preferred brands ($20, $50 copay)
• Tier 3: Non-preferred brands ($50, $100 copay or 30 to 40% coinsurance)
• Tier 4/5: Specialty or non-formulary (highest cost sharing or full price)

Generic MAS IR typically lands at Tier 1 or Tier 2. Generic MAS XR commonly sits at Tier 2. Brand Adderall XR has historically appeared at Tier 3 or higher. Vyvanse (lisdexamfetamine) is a separate molecular entity and is discussed in the alternatives section below.

Prior Authorization Criteria Security Health Plan Commonly Applies

Although Security Health Plan does not publish every internal clinical criterion publicly, stimulant PA criteria across Wisconsin Medicaid and comparable commercial plans consistently require: [5]

1. A confirmed ADHD diagnosis from a licensed provider, documented with DSM-5 criteria. [6]
2. The patient's age (most PA criteria start at age 6 for IR formulations).
3. Adequate trial of a generic IR stimulant if requesting an XR or brand formulation.
4. Absence of contraindications such as uncontrolled hypertension or symptomatic cardiovascular disease.
5. Documentation that the requested dose is within FDA-labeled dosing ranges. [1]

Your prescriber submits this information to Security Health Plan's pharmacy benefit manager. Approval can come within 24 to 72 hours for standard requests. An expedited PA, used when a denial would seriously harm the patient, must be resolved within 72 hours under federal managed care rules. [7]

Step Therapy: What It Means for Your Prescription

Step therapy requires a patient to try and fail one or more preferred medications before the insurer covers the requested drug. Security Health Plan, like most Wisconsin commercial insurers, applies step therapy to ADHD stimulants. The typical step sequence is:

1. Generic amphetamine/dextroamphetamine IR (Adderall generic), first step
2. Generic amphetamine/dextroamphetamine XR (Adderall XR generic), second step
3. Brand Adderall XR or alternative agents (Vyvanse, Mydayis), after documented failure or intolerance

When Step Therapy Can Be Bypassed

Wisconsin Act 146 (2017) and federal Mental Health Parity regulations give patients and prescribers the right to request a step-therapy exception when: [8]

• The patient has already tried and failed the required step-therapy drug.
• The required drug is contraindicated or likely to cause an adverse reaction.
• The patient is stable on the requested medication and a switch would destabilize them.

Your prescriber must document the exception request in writing. Security Health Plan is required to respond to step-therapy exception requests within the same timeframe as standard PA requests.

Methylphenidate as an Alternative First Step

Some Security Health Plan plan designs place methylphenidate-based medications (Ritalin, Concerta, generics) as the preferred first-line stimulant rather than amphetamine salts. Methylphenidate and amphetamine are both endorsed as first-line ADHD pharmacotherapy by the American Academy of Pediatrics 2019 clinical practice guideline. [9] If your plan requires a methylphenidate trial first, your prescriber will need to document that trial before Adderall is covered.

How Prior Authorization Actually Works: A Step-by-Step View

Getting through a PA does not have to be a months-long process, but it does require your prescriber's office to act quickly and completely.

Step 1: Prescriber Submits PA Request

Your provider sends Security Health Plan (or its pharmacy benefit manager) a PA form by fax, electronic submission, or phone. The form requests diagnosis codes, current medications, clinical notes, and the specific drug and dose requested. Incomplete submissions are the most common reason for delays.

Step 2: Clinical Review

A pharmacist or physician at the plan reviews the submission against Security Health Plan's clinical criteria. The American Academy of Child and Adolescent Psychiatry (AACAP) practice parameter for ADHD is often the clinical backbone insurers use. [10] If criteria are met, approval issues automatically.

Step 3: Approval, Denial, or Request for Additional Information

An approval means your pharmacy can fill the prescription at the formulary tier's copay. A denial triggers your right to appeal. A request for additional information pauses the clock until your provider responds.

Step 4: Dispensing with Quantity Limits

Even after PA approval, Security Health Plan imposes quantity limits. A 30-day supply per fill is standard for Schedule II stimulants, matching DEA regulations. [2] Some plans allow a 90-day supply for mail-order pharmacy on select medications, but Schedule II stimulants are typically excluded from this option at the federal level.

What Happens When Security Health Plan Denies Adderall Coverage?

A denial is not final. Federal law under the ACA and Wisconsin state insurance law give you structured appeal rights. [11]

Internal Appeal

File an internal appeal within 30 days of receiving the denial notice. Your prescriber should submit a letter of medical necessity alongside updated clinical documentation. The AACAP 2023 practice parameter states that "stimulant medications are the most effective pharmacological treatment for ADHD, with effect sizes of 0.8 to 1.0 in children and adolescents." [10] That evidence standard supports medical necessity arguments.

External Review

If the internal appeal fails, you have the right to an independent external review. In Wisconsin, the Office of the Commissioner of Insurance oversees external reviews. [12] External reviewers are board-certified physicians with no financial relationship to the insurer. Approximately 40 to 45% of external reviews nationally result in the insurer's decision being overturned, according to CMS data. [13]

Expedited Appeal for Urgent Situations

If your provider documents that waiting would cause serious harm, for example, a child whose ADHD is so severe that lack of medication creates a safety risk, you can request an expedited appeal. Security Health Plan must respond within 72 hours. [7]

Using Manufacturer Coupons While Appealing

Shire (now Takeda) and other manufacturers offer copay assistance programs for brand Adderall XR. These programs typically exclude patients on government-funded plans (Medicaid, Medicare). For commercially insured members who are mid-appeal, a manufacturer coupon can reduce out-of-pocket costs to as low as $0 per month during the appeal period. Check the manufacturer's website directly; program terms change annually.

ADHD Medications Covered by Security Health Plan as Alternatives

If Adderall coverage is delayed or denied, several alternatives are typically on the Security Health Plan formulary at lower cost-sharing tiers.

Methylphenidate-Based Options

• Methylphenidate IR (generic Ritalin): Typically Tier 1; FDA approved for ADHD in children aged 6 and older and adults. [14]
• Methylphenidate ER (generic Concerta, generic Ritalin LA): Tier 1 or Tier 2; provides 8 to 12 hours of coverage.
• Methylphenidate patch (Daytrana): Higher tier; rarely preferred by formulary managers.

Amphetamine-Based Options

• Generic MAS IR (generic Adderall): Usually the lowest-tier amphetamine option.
• Lisdexamfetamine (Vyvanse): Typically Tier 3 or higher; a prodrug with a lower abuse profile, though FDA approved for ADHD and moderate-to-severe binge eating disorder. [15]
• Dextroamphetamine IR (generic Dexedrine): Tier 1 or Tier 2 in many plans.

Non-Stimulant Options

When stimulants are contraindicated or refused, non-stimulants are an option. Atomoxetine (generic Strattera) carries an FDA indication for ADHD in children aged 6 and older, adolescents, and adults. [16] Guanfacine ER (generic Intuniv) and clonidine ER (generic Kapvay) are FDA approved for pediatric ADHD. [17, 18] These agents typically sit at Tier 1 or Tier 2 given their generic availability. Effect sizes for non-stimulants are smaller than for stimulants, roughly 0.4 to 0.6 vs. 0.8 to 1.0, but they remain clinically meaningful for the right patient. [19]

ADHD Treatment: The Clinical Evidence Supporting Medication

Understanding why a prescriber is fighting for Adderall coverage requires understanding the clinical evidence base.

The MTA Study

The Multimodal Treatment of ADHD (MTA) study (N=579) remains the landmark long-term RCT in childhood ADHD. Published in 1999 in the Archives of General Psychiatry, it found that carefully managed medication produced significantly greater improvement in ADHD symptom scores than behavioral therapy alone or community care at 14 months. [20] Follow-up analyses at 24 months confirmed sustained benefits for medication-managed children. [21]

Adult ADHD Evidence

Adult ADHD is often under-recognized and under-treated. A 2016 meta-analysis in The Lancet Psychiatry (N=12 studies, N=2,801 adults) found amphetamines produced a standardized mean difference of 0.79 (P<0.001) versus placebo on ADHD symptom rating scales. [22] Methylphenidate showed a standardized mean difference of 0.49 (P<0.001) in a separate analysis. That gap in effect size is one clinical rationale prescribers cite when arguing that a patient needs amphetamines specifically after failing methylphenidate.

Cardiovascular Considerations

The FDA-approved labeling for amphetamine salts includes a boxed warning about cardiovascular risk and potential for abuse. [1] A 2011 NEJM cohort study (N=1,200,438 children and young adults) found no significant increase in serious cardiovascular events among ADHD medication users compared with non-users (adjusted hazard ratio 0.75, 95% CI 0.31 to 1.85). [23] Still, Security Health Plan's PA criteria may require documentation that the patient has no uncontrolled hypertension or structural heart disease before approving stimulants. The American Heart Association recommends baseline cardiovascular screening before initiating stimulant therapy. [24]

Wisconsin Medicaid and Security Health Plan BadgerCare Coverage

Security Health Plan administers BadgerCare Plus managed care plans in Wisconsin. Adderall coverage under BadgerCare Plus follows Wisconsin Medicaid's preferred drug list (PDL), which is managed by DHS. [25] Generic amphetamine/dextroamphetamine IR and XR are on the Wisconsin Medicaid PDL. PA is still required. BadgerCare members can check the current PDL at the Wisconsin DHS website or call ForwardHealth member services.

Income-Based Assistance Programs

Members with incomes at or below 138% of the federal poverty level may qualify for BadgerCare Plus. At that income level, prescription copays are capped under Medicaid rules, making Adderall generics effectively low-cost after PA approval. [26]

What to Tell Your Prescriber Before They Submit the PA

Speed and completeness determine whether a PA gets approved on the first submission or bounces back for more information.

Key Documentation Your Provider Should Include

• DSM-5 diagnostic criteria met (inattentive, hyperactive-impulsive, or combined presentation). [6]
• Age of symptom onset before age 12, as required by DSM-5.
• Functional impairment documented in at least two settings (school/work and home).
• Any previous stimulant or non-stimulant trials, including doses and reasons for discontinuation.
• Current vital signs, especially blood pressure and heart rate, to address cardiovascular safety screening.
• Target symptoms and measurable treatment goals (e.g., Conners Rating Scale score at baseline).

The AACAP recommends using validated rating scales, such as the Vanderbilt ADHD Rating Scale or the Conners, at baseline and follow-up to document treatment response. [10] Including a baseline Vanderbilt score in the PA packet gives Security Health Plan's reviewer objective data, which strengthens the approval case.

Monitoring Requirements After Coverage Is Approved

Security Health Plan may require periodic re-authorization for Adderall, typically every 12 months. Your prescriber should schedule at least two follow-up visits in the first year: one at 4 to 6 weeks after initiation to assess response and side effects, and one at 6 to 12 months to document ongoing benefit. [9]

What Gets Monitored

• Blood pressure and heart rate at each stimulant follow-up visit.
• Height and weight in pediatric patients, because amphetamines can suppress appetite and slow growth velocity at high doses. [1]
• Symptom rating scales (Vanderbilt, Conners, or ADHD-RS) to document continued therapeutic benefit.
• Substance use screening, particularly in adolescents and young adults.

The FDA requires a medication guide be dispensed with each Adderall fill, covering abuse potential, cardiovascular risk, and psychiatric side effects. [1] Patients and families should read this guide and raise any concerns with their prescriber before the next PA renewal is due.